ReviewDiscover nano2025
2009-2023 Bibliometric analysis of the clinical value of graphene quantum dots in glioblastoma treatment.
Review in Discover nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Glioblastoma (GBM) is the most common primary brain tumour in adults and poses a serious health risk. Graphene quantum dots (GQDs) are zero-dimensional crystalline discs de-rived from two-dimensional graphene, which contribution of GQDs in the treatment of GBM and the great potential for future development. In this study, the Web of Science database was applied to search 462 relevant papers published between 2009 and 2023, and analyzed using VOS viewer and CiteSpace software tools. This analysis aims to provide researchers with insights into the current state of applications and to facilitate a clearer understanding of potential pathways and directions for future research in this field. Our study showed a continuous increase in the number of papers about GQDs in the treatment of GBM. In the field for more than a decade, GQDs has been a research priority in drug delivery due to their excellent optical and chemical properties. It is reasonable to believe that the use of GQDs for drug delivery for the treatment of GBM will be-come one of the extremely important research topics in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.